Investors often overlook SEC filings, and it is the job of the 10Q Detective to dig through businesses’ 8-K and 10-Q SEC filings, looking for financial statement ‘soft spots,'(depreciation policies, warranty reserves, and restructuring charges, etc.)that may materially impact Quality of Earnings.
Wednesday, December 16, 2009
How Much For Life? Allos Therapeutics Says $30,000 - Per Month
The cost of Folotyn (pralatrexate injection) runs about $120,000 a year, a price tag that few drugs for incurable, rare cancers can match. With the runaway cost of healthcare under intense debate, critics contend that Allos Therapeutics' (ALTH-$5.99) drug for for relapsing or refractory peripheral T-cell lymphoma is excessive — especially since clinical benefit, such as improvement in progression-free survival or prolonging life, has not been demonstrated. In the pivotal PROPEL trial that led to FDA approval, duration of response was, on average, 9.4 months and the mean overall survival time was 14.7 months.